MyMD Pharmaceuticals Enrolls First Individual in Stage 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Expanding Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Firm”), a clinical phase pharmaceutical business devoted to extending healthy and balanced lifespan, today revealed that the first person has been registered in the Firm’s Phase 2 clinical test of lead candidate MYMD-1, a dental immune regulator drug, as a therapy for delaying aging as well as broadening healthy and balanced life expectancy.

The primary endpoint for the Stage 2 double-blind, placebo-controlled medical trial is to achieve a reduction in the distributing degrees of (TNF-α), growth necrosis variable receptor I (TNFRI) and also IL-6. TNF-α and also IL-6 are the proteins in the body that cause swelling and aid turn on the procedure of aging. The additional measures of the trial will certainly be the safety and security, tolerability, and also pharmacokinetics in this populace of people.

” In a Phase 1 scientific test of MYMD-1, we showed the drug’s statistically significant effectiveness in lowering degrees of TNF-α, a principal in causing pathological aging, in the blood. The FDA has accepted TNF-α reduction as the key endpoint for our Phase 2 research, which our team believe positions us well for a successful Stage 2 result,” said Chris Chapman, M.D., Head Of State, Supervisor as well as Chief Medical Policeman of MyMD. “The initiation of person enrollment in this research study developments our objective to slow the aging process, protect against loss of muscle cells in aging, limitation frailty, as well as prolong healthy and balanced lifespan.”

MyMD has mentioned that there are no FDA-approved medications for dealing with aging problems and also prolonging healthy lifespan human beings, a market expected to be a minimum of $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are one of the most prescribed medicines by earnings, an international market of around $40 billion annually,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would certainly enhance life expectancy by one year is worth $38 trillion and by one decade is worth $367 trillion.

In addition to aging, MYMD-1’s distinct action in controling the body immune system as well as treating chronic inflammation is being developed for the treatment of autoimmune condition, consisting of rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes, and also inflammatory bowel condition.

” We intend to start composing protocols for a Stage 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The increasing frequency of rheumatoid joint inflammation as well as other autoimmune and inflammatory illness are driving demand for TNF preventions like MYMD-1, as well as our team believe our orally provided medicine with extremely reduced poisoning would be turbulent to the $60 billion market for RA if approved by the FDA for this indicator.”

Rheumatoid joint inflammation affects around 40 million individuals around the world.4.

Regarding MYMD-1.

Initially created for autoimmune diseases, MYMD-1’s key function is to reduce the aging process, prevent sarcopenia and also frailty, and prolong healthy and balanced life expectancy. Because it can cross the blood-brain barrier and get to the central nerves (CNS), MYMD-1 is likewise placed to be a possible therapy for brain-related disorders. Its system of action and also effectiveness in conditions consisting of numerous sclerosis (MS) and thyroiditis have actually been researched via collaborations with a number of scholastic institutions. MYMD-1 is additionally showing promise in pre-clinical research studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation healing.

MYMD-1 has actually shown effectiveness in pre-clinical research studies in regulating the body immune system by doing as a discerning inhibitor of tumor death factor-alpha (TNF-α), a vehicle driver of chronic inflammation. Unlike various other therapies, MYMD-1 has actually been received these pre-clinical research studies to selectively obstruct TNF-α when it becomes overactivated in autoimmune illness and cytokine tornados, but not obstruct it from doing its regular work of being a first -responder to any kind of routine kind of moderate infection. MYMD-1’s convenience of oral application is another differentiator compared to presently offered TNF-α blockers, all of which call for delivery by injection or infusion. No approved TNF prevention has ever before been dosed by mouth. Additionally, the medication is not immunosuppressive as well as has actually not been shown to create the major adverse effects typical with traditional therapies that treat swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical business devoted to expanding healthy life-span, is focused on developing 2 unique healing platforms that treat the reasons for illness instead of just attending to the symptoms. MYMD-1 is a drug system based on a clinical stage little molecule that regulates the immune system to manage TNF-α, which drives persistent inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to delay aging, rise longevity, and deal with autoimmune illness as well as COVID-19- connected clinical depression. The Business’s 2nd medicine platform, Supera-CBD, is being established to treat chronic pain, addiction and also epilepsy. Supera-CBD is a novel artificial by-product of cannabidiol (CBD) and is being established to deal with and also improve upon the rapidly growing CBD market, that includes both FDA approved drugs and CBD products not presently regulated as medicines. To find out more, check out www.mymd.com.

Comments are closed.